Bristol-Myers Squibb BMY Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockValue.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding?
- Bristol-Myers Squibb (BMY) reported preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding of $0 in Q1 2026.
- What does preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding mean?
- The value of equity shares that have priority over common stock for dividends and assets.
- How do you interpret preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding?
- The presence of preferred stock indicates a specific capital structure choice, often used to raise capital without diluting common shareholders or increasing debt leverage.
- How does preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding compare across companies?
- Less common than common stock; used strategically by companies to optimize their cost of capital.